

Cardiovascular Outcomes of Differentiated Thyroid Cancer Patients on Long Term TSH Suppression: A Systematic Review and Meta-Analysis

Authors

Jerry Yu¹, Rajneesh Kaur¹, Femi Emmanuel Ayeni² , Guy D. Eslick¹, Senarath Edirimanne³

Affiliations

- 1 Sydney Medical School, The University of Sydney, Sydney, Australia
- 2 Nepean Institute of Academic Surgery, Nepean Clinical School, The University of Sydney, Sydney, Australia
- 3 Dept of Surgery, Nepean Hospital, Penrith, Australia

Key words

TSH suppression, cardiovascular disease, thyroid malignancy, heart disease, thyroid cancer

received 25.10.2022

accepted after revision 21.04.2023

Bibliography

Horm Metab Res 2023; 55: 379–387

DOI 10.1055/a-2084-3408

ISSN 0018-5043

© 2023, Thieme. All rights reserved.

Georg Thieme Verlag, Rüdigerstraße 14,
70469 Stuttgart, Germany

Correspondence

Dr. Femi Emmanuel Ayeni
Nepean Institute of Academic Surgery, Nepean Clinical
School, The University of Sydney
62 Derby Street, Kingswood, Sydney, NSW 2747
Australia
Tel.: +61 2 4734 2609
femi.ayeni@sydney.edu.au



Supplementary material is available under <https://doi.org/10.1055/a-2084-3408>

ABSTRACT

We performed a systematic review and meta-analysis of the literature regarding cardiovascular outcomes of differentiated thyroid cancer (DTC) patients who are on long term thyroid stimulating hormone suppression. Searches were carried out using Prisma guidelines in Medline, Embase, CENTRAL, CINAHL and Scopus databases. Eligible papers were those which investigated discrete cardiovascular clinical outcomes in TSH suppressed patients and meta-analysis of selected studies was performed using Revman 5.4.1. We found a total of 195 879 DTC patients with median length to follow up of 8.6 years (range 5–18.8 years). Analysis showed DTC patients to be at higher risk of atrial fibrillation (HR 1.58, 95% CI 1.40, 1.77), stroke (HR 1.14, 95% CI 1.09, 1.20) and all-cause mortality (HR 2.04, 95% CI 1.02, 4.07). However, there was no difference in risk of heart failure, ischemic heart disease or cardiovascular mortality. These findings suggest that degree of TSH suppression must be titrated to accommodate risk of cancer recurrence and cardiovascular morbidity.

Introduction

The global incidence of thyroid carcinoma has been rapidly increasing over the past three decades [1]. This is largely due to increasing diagnostic yield, with unchanged mortality rates [2]. Differentiated thyroid cancer (DTC) accounts for over 95% of thyroid malignancies [3]. These patients often have an excellent prognosis, with 10-year survival rates exceeding 90% [4, 5].

DTC patients typically receive partial or total thyroidectomy as curative treatment for their condition [6]. They may also receive radioactive iodine treatment (RAI) to ablate remaining thyroid

tissue that was not removed by surgery [6]. Thyroid stimulating hormone (TSH) is known to stimulate proliferation of thyroid cancer cells [3]. Hence patients often receive long term TSH suppression post-surgery in the form of iatrogenic levothyroxine supplementation, to reduce the risk of cancer recurrence and cancer-associated mortality [7].

The most common cause of subclinical hyperthyroidism is iatrogenic levothyroxine treatment, hence a state of exogenous subclinical hyperthyroidism is often induced in DTC patients [8]. There is an increasing body of evidence that suggests this is associated

with increased cardiovascular morbidity and mortality [8, 9]. It is well established that subclinical hyperthyroidism is a risk factor for atrial fibrillation [10, 11]. There are also numerous physiological complications associated with TSH suppressive therapy, such as increased left ventricular mass, tachycardia [12], diastolic dysfunction [13], impaired arterial elasticity [14], and negative prothrombotic changes [15].

Whilst the optimal degree of TSH suppression with regards to cancer recurrence risk is well established, there is a lack of guidelines which optimally correlate TSH suppression and cardiac morbidity [16]. Synthetic dosing requires dynamic reassessment with respect to the individual's risk of cancer recurrence and cardiovascular health [17]. With the exception of atrial fibrillation, there is limited research investigating the discrete clinical outcomes of TSH suppressed DTC patients. Rather the literature is largely focused on surrogate clinical parameters. This review includes several large cohort studies published since the last systematic review on the topic, hence it better evaluated the cardiovascular clinical outcomes of DTC patients on long-term TSH suppression. It is also the first meta-analysis to offer quantitative estimations of risk. Specifically, this review investigated the cardiovascular morbidity of treatment and whether these patients experienced higher incident rates of cardiovascular disease.

Materials and Methods

Systematic search strategy

The literature search was conducted through Medline (1947 to 22 July 2021), Embase (1946 to 22 July 2021), and CENTRAL (1991 to 22 July 2021). Search terms included numerous keywords pertaining to the cardiovascular outcomes of DTC patients on long term TSH suppression (**Supplementary Fig. 1S**). The search was adapted for the databases CINAHL and Scopus. Further papers were identified from previous systematic reviews relevant to the topic.

Study selection – Inclusion/exclusion criteria

The study selection followed the PRISMA guidelines. No formal study protocol was lodged. Two reviewers (JY and SE) used Endnote to collate the results from the literature search and duplicates were deleted. The results were initially screened by title and abstract. Full texts were subsequently retrieved and screened for inclusion into the review.

Eligibility criteria for studies included those which investigated DTC patients who received long-term TSH suppression as part of their treatment regimen. Further, the studies were included if results were reported as measures of discrete cardiovascular clinical outcomes such as incident atrial fibrillation, stroke, ischaemic heart disease, heart failure, cardiovascular mortality, all-cause mortality, etc.

Studies that did not meet all these criteria were excluded. Specifically, studies that investigated patients with poorly differentiated thyroid cancer, non-cancer thyroid conditions and patients on short-term TSH suppression were excluded. Studies that reported their results in clinical parameters of cardiovascular disease as opposed to discrete clinical outcomes such as echocardiographic find-

ings, heart rate variability were also excluded. Furthermore, animal studies and non-English studies were excluded. There was no restriction on publication type or date.

Data extraction, analysis, and quality assessment

Data were extracted from the relevant included studies and compiled into a master excel spreadsheet stratified into demographic and outcome features. The demographic data included: i) author, ii) year, iii) country of publication, iv) baseline data collection year, v) type of study, vi) length to follow up, vii) total participants, viii) study group, ix) control group, x) male/female ratio, xi) age participants, xii) measure used (age), and xiii) TSH levels measured. If TSH levels were not available, it was assumed that patients were TSH suppressed as per the relevant country's national guidelines.

The following data were extracted from included studies: i) reported study effects, ii) measure used, iii) effect size, iv) lower 95% CI, v) upper 95% CI, vi) reference category, vii) was analysis adjusted, and viii) adjusted for what measures.

Two independent reviewers (JY and RK) performed a risk of bias and quality assessment of included studies using the Newcastle-Ottawa Scale, which evaluated the three domains of patient selection, comparability, and outcome. Scores ranged from 0–9 and studies with scores of 6 or greater were considered high quality (**Supplementary Table 1S**). Consensus was reached for all differences.


Statistical analysis

Review manager 5.4.1 was utilised for data analysis. The studies were combined by the generic inverse-variance method on the natural logarithms of hazard ratios (HR). Hazard ratios (HR) were reported with 95% confidence intervals. If specific hazard ratios were not reported in a paper, these were generated from available raw data, that is, number of participants and events in the study and control groups. Some of the papers reported follow up in mean and other reported follow up in median. So, we took a median of the combined means and medians to obtain length to follow up. Test of overall effects and statistically significant results were reported with pooled hazard ratios.

Meta-analysis was performed on outcomes assessed by more than two studies. The χ^2 test was used to assess heterogeneity, and this was quantified with the I^2 value. Heterogeneity was characterised as: $I^2 < 25\%$ none; $I^2 25\text{--}49\%$ low; $I^2 50\text{--}74\%$ medium; $I^2 > 75\%$ high. Both random and fixed effect models were used for the meta-analysis depending on the I^2 value. Random effect models were used for medium to high I^2 values and fixed effect models were used for low to medium I^2 values. Significance level was set at < 0.05 . Funnel plots were created with RevMan 5.4.1 to assess for potential publication bias and small study effects (**Supplementary Fig. 2S**).

Results

The systematic search yielded 130 papers once the duplicates were removed. These studies were screened by title and abstract, of which 100 were excluded and 30 were sought for retrieval. 29 full text studies were reviewed, and one full text was unable to be retrieved. 19 studies did not fulfil the inclusion criteria. 10 studies



► **Fig. 1** PRISMA diagram of literature search and screening.

were included into the review. The PRISMA diagram is shown in ► **Fig. 1**.

Of the included papers, six were European studies [18–23], three were from the US and Canada [24–26], and one was from South Korea [27]. All studies were published within the previous decade. Nine papers were cohort studies, and one paper was a cross-sectional study (► **Table 1**). The quality of included studies was assessed as high via the Newcastle–Ottawa scale (**Supplementary Table 15**). There was a total of 195 879 patients and 204 595 controls across the papers. Median length to follow up was 8.6 years. ► **Table 2** summarises key characteristics of the included papers.


Cardiovascular morbidity

All studies investigated cardiovascular morbidity or mortality. The outcomes and key findings are summarised in ► **Table 2**. The subjects were DTC patients undergoing long-term TSH suppression therapy. Unless stated otherwise, controls were healthy, non-TSH


suppressed individuals with findings adjusted for age, sex, and variable degrees of social and cardiovascular risk factors. Two papers used population based cohorts, without specified numbers of control subjects, as the reference group [23, 24]. In two other papers, the control groups were non-TSH suppressed DTC patients [25, 26]. The reference categories and details of analysis adjustment are summarised in **Supplementary Table 35**. Heterogeneity ranged between 16–98% across outcomes (► **Fig. 2–6**).

Cardiovascular and all-cause mortality


Two studies reported on cardiovascular mortality and three studies reported on all-cause mortality (► **Fig. 2**) [18, 21, 22]. Hesselink et al. reported increased cardiovascular mortality among 524 DTC patients [18]. Pajamaki et al. reported decreased cardiovascular mortality among 901 DTC patients [21]. All-cause mortality was significantly increased among DTC patients (4434 patients, HR 2.04, 95% CI 1.02, 4.07).



► Fig. 2 Meta-analysis summarising cardiovascular findings (all-cause mortality).



► Fig. 3 Meta-analysis summarising cardiovascular findings (atrial fibrillation).



► Fig. 4 Meta-analysis summarising cardiovascular findings (stroke).

Atrial fibrillation

Atrial fibrillation (AF) was measured in eight studies (► Fig. 3) [19–24, 26, 27]. No occurrences of AF were observed in a study of 66 DTC patients, hence, it was not included in the statistical analysis [20]. Risk of AF was significantly increased among DTC patients compared to controls (194 212 patients, HR 1.58, 95% CI 1.40, 1.77). Suh et al. demonstrated a dose dependent effect whereby increased doses of levothyroxine (TSH suppression) lead to an increased risk of AF [27].

Stroke/cerebrovascular disease

Stroke and cerebrovascular disease were investigated by five papers (► Fig. 4) [21–23, 25, 27]. DTC patients were at higher risk of


stroke and cerebrovascular disease than controls (194 170 patients, HR 1.14, 95% CI 1.09, 1.20).

Ischaemic/coronary heart disease


Five studies reported on ischaemic heart disease (► Fig. 5) [21–23, 25, 27]. There was no difference in ischaemic heart disease (IHD) risk between DTC patients and controls (194 170 patients, HR 1.07, 95% CI 0.99, 1.16).

Heart failure

Three studies investigated occurrence of heart failure in DTC patients (► Fig. 6). There was no difference in HF incidence between DTC patients and controls (10 810 patients, HR 0.99, 95% CI 0.78, 1.26).



► Fig. 5 Meta-analysis summarising cardiovascular findings (ischaemic heart disease).



► Fig. 6 Meta-analysis summarising cardiovascular findings (heart failure).

Other CVD outcomes

The study by Pajamaki et al. also investigated a number of other cardiovascular outcomes not previously mentioned. These included hypertension, arteriovenous disease, valvular disease, cardiomyopathies and disease of the pulmonary arteries in their group of 901 patients and 4485 controls [21]. For all outcomes, there was no difference in incidence between TSH suppressed DTC patients and healthy controls [21]. The study showed an increased risk of all arrhythmias in the DTC cohort compared to controls. Further, when pooling the cardiovascular outcomes together the study demonstrated a significantly increased risk of cardiovascular morbidity in DTC patients [21].

Park et al. also investigated several other cardiovascular outcomes, namely hypertension, arterial disease, and venous disease. The study showed that DTC patients receiving TSH suppression therapy were at increased risk of hypertension and disease of the arteries, arterioles and capillaries, when compared to DTC patients who did not receive TSH suppressive therapy [25]. There was no difference in incidence of venous disease between TSH suppressed and non-TSH suppressed patients [25].

Degree of TSH suppression and cardiovascular outcomes

There was variability in the degree of TSH suppression and the way in which it was measured across studies, different guidelines of suppression were used depending on where the study was conducted (**Supplementary Table 2S**). Three studies showed no relationship between degree of TSH suppression and incidence/prevalence of

AF [19, 24, 26]. The degree of TSH suppressive therapy was difficult to interpret some of the studies. Toulis et al. assumed TSH suppression to be within British guidelines, however not all TSH measurements of the patients were available, hence the extent of suppressive therapy was not reported [22]. Similarly, Zoltek et al. assumed TSH suppression to be in line with Swedish national guidelines, although specific measurements were not reported [23]. Suh et al. measured levothyroxine dose as a proxy marker for the degree of TSH suppression [27]. This study showed a dose dependent increase in AF, stroke and IHD incidence with increasing levothyroxine dose [27]. Another study reported that lower TSH levels were associated with increased cardiovascular mortality [18]. Further, Pajamaki et al. reported increased CVD morbidity in patients with TSH levels below 0.1 mIU/l [21]. Park et al. demonstrated an association between TSH suppression and increased risk of hypertension and arterial disease [25]. These findings are summarised in **Supplementary Table 2S**.

Discussion

The primary aim of this study was to better evaluate discrete cardiovascular outcomes in TSH suppressed DTC patients. The results demonstrated a number of adverse cardiovascular diseases associated with long term DTC management. Although there is a paucity of studies investigating discrete adverse cardiovascular events in the given setting, this review has included two large population-based cohort studies [23, 27], which have not been included in previous qualitative reviews, and also affords quantitative data

▶ **Table 1** Overview of included studies.

Authors [Ref]	Year	Country	Baseline data collection year-year of DTC diagnosis	Type of study	Length to follow up (Years)	Total participants	#Study group	#Control group	M/F	Age of participants	SD age participants	Measure Used Age	TSH Levels measured
Abonowara et al. [24]	2012	Canada	2009–2010	Cross-sectional	11.0	136	136	NR	18/118	52	NR	Mean	Yes
Klein Hesselink et al. [19]	2015	Netherlands	1980–2010	Cohort	8.7	2081	518	1563	530/1551	48.6	14	Mean	Yes
Klein Hesselink et al. [18]	2013	Netherlands	1980–2010	Cohort	8.5	2096	524	1572	536/1560	49	14	Mean	Yes
Klein Hesselink et al. [20]	2017	Netherlands	1970–2009	Cohort	17.0	132	66	66	18/114	33	NR	Median	Yes
Park et al. [25]	2018	USA	1997–2012	Cohort	8.4	3822	941	2881	816/3006	NR	NR	NR	No
Pajamaki et al. [21]	2018	Finland	1981–2002	Cohort	18.8	5386	901	4485	1003/4383	48.8	15.9	Mean	Yes
Suh et al. [27]	2019	South Korea	2004–2012	Cohort	4.3	364838	182419	182419	57736/307102	47	11.3	Mean	No
Toullis et al. [22]	2019	UK	1996–2016	Cohort	5.0	14312	3009	11303	3414/10898	50.5	NR	Mean	No
Wang et al. [26]	2015	USA	2000–2006	Cohort	6.5	771	465	306	202/569	48	14	Mean	Yes
Zoltek et al. [23]	2020	Sweden	1987–2013	Cohort	9.6	NR	6900	NR	1812/5088	NR	NR	NR	No

▶ **Table 2** Investigated outcomes and key findings of papers.

Authors [Ref]	Outcomes studied	Significant positive findings vs. control/reference group
Abonowara[24]	AF	Increased prevalence AF
Hesselink[19]	AF	Increased incidence AF
Klein Hesselink[18]	CVD Mortality, All Cause Mortality	Increased incidence CVD mortality and all cause mortality
Klein Hesselink[20]	AF	Nil
Park[25]	HTN, Heart Disease, Cerebrovascular Disease, Disease of Arteries/Arterioles/Capillaries, Venous and Lymphatic Disease	Increased incidence HTN and arterial disease
Pajamaki[21]	CVD Mortality, CVD Morbidity, All Cause Mortality, All Arrhythmias, AF, HF, HTN, Cerebrovascular Disease, Vascular Disease, CAD, Cardiomyopathy/Valvular Disease, Pulmonary Artery Disease	Increased incidence AF, all arrhythmias, CVD morbidity Reduced CVD mortality
Suh[27]	AF, Stroke, CHD	Increased incidence AF, stroke, CHD
Toullis[22]	AF, All Cause Mortality, Stroke, HF, IHD	Increased incidence AF, stroke, all cause mortality
Wang[26]	AF	Nil
Zoltek[23]	AF, Stroke, IHD, HF, Cerebrovascular Disease, Ischaemic Heart Attack	Increased incidence AF, cerebrovascular disease

AF: Atrial fibrillation; CVD: Cardiovascular disease; HTN: Hypertension; HF: Heart failure; CAD: Coronary artery disease; CHD: Coronary heart disease; IHD: Ischaemic heart disease.

in the form of a meta-analysis. Further, the high quality of studies as per the Newcastle-Ottawa scale suggests that there is a low risk of bias with regards to patient selection, comparability of cohorts and outcome assessment across the papers.

This study demonstrated that DTC patients experience increased rates of AF. Pathophysiological mechanisms involve the positive chronotropic and dromotropic effects of exogenous thyroxine administration and subsequent iatrogenic subclinical hyperthyroidism [28]. Thyroid hormone excess is associated with an increased resting heart rate, impaired ventricular relaxation and increased left ventricular mass which leads to elevated left atrial pressures [12, 28]. Increased atrial ectopic activity is also associated with thyrotoxicosis [28]. All of these factors may contribute to the increased rates of AF in DTC patients.

Risk of stroke was increased in DTC patients, and Suh et al. further demonstrated a dose-dependent increased risk of stroke with increasing TSH suppressive therapy [27]. A central mechanism underlying this association is the increased rates of AF in DTC patients. It is well established that AF predisposes to cardiac thrombus formation and hence may lead to a greater risk of ischaemic stroke [29]. Suh et al. also demonstrated an increased risk of stroke independent of atrial fibrillation, suggesting that other pathophysiological mechanisms may be in effect. It is plausible that hypercoagulability, systolic hypertension and increased arterial stiffness associated with iatrogenic hyperthyroidism may be partially responsible for the increased rates of stroke in DTC patients [30].

The two papers investigating CVD mortality produced opposing findings. Pajamaki et al. reported a decreased CVD mortality in DTC patients [21]. This was attributed to the excellent survival rates associated with DTC [4, 5, 31], combined with the lifelong follow up of DTC patients, which encourages continued interaction with the medical community [21]. Further, patients that die due to cancer are unable to reach a cardiovascular endpoint hence resulting in lower cardiovascular mortality [32]. Conversely, Hesselink et al. showed increased cardiovascular mortality in DTC patients [18]. Although the pathophysiological mechanisms are not clearly understood, it may be associated with increased left ventricular mass, AF and decreased diastolic function in TSH suppressed patients [13, 14, 33]. There were numerous methodological differences between the studies. Hesselink et al. controlled for cardiovascular risk factors whereas Pajamaki et al. did not. The two cohorts were subject to differing degrees of TSH suppression, and length to follow-up was over twice as long in the study by Pajamaki et al. Further studies are required to better evaluate this outcome. All-cause mortality was significantly increased in DTC patients. It is possible that elements of both CVD mortality and cancer related mortality contributed to this.

DTC patients were found to be at a mildly higher risk of IHD than controls, although this was not statistically significant. Four of five studies showed no evidence of difference. The only positive significant finding was demonstrated by Suh et al., which had marked greater statistical power than the other studies, with a sample size of 182 419 as opposed to 11 751 combined across the other papers. Suh et al. also demonstrated a dose-dependent increase in IHD risk with increasing levothyroxine administration [27]. It was proposed that the possible underlying mechanisms are similar to those affecting ischaemic stroke risk in the TSH suppressed, that is, systolic hypertension, hypercoagulability, increased arterial stiffness and enhanced LDL oxidation [30, 34].

Surprisingly, no difference in heart failure risk was appreciated between DTC patients and controls. It is possible that the subclinical nature of hyperthyroidism experienced by patients is not sufficient to cause overt clinical heart failure. Investigation of clinical parameters may better elucidate this association. It has been shown that left ventricular ejection fraction decreases with TSH suppression lasting over 12 months [35]. Regarding other outcomes, Park et al. showed an increase in hypertension and arterial disease in TSH suppressed patients [25], attributing this to the myocardial and vascular function impairment associated with long term suppression [14]. Further studies are required to better characterise the additional outcomes investigated by Pajamaki et al. [21].

This review also demonstrates that the association of adverse cardiovascular outcomes in DTC patients is multifactorial and not only attributable to TSH suppressive therapy. Surprisingly, three studies showed no difference between TSH levels and risk of AF [19, 24, 26]. This finding may be due to underpowered studies coupled with varied degrees of TSH suppression between patients [19, 24, 26]. Further, there is possible surveillance bias associated with subclinical paroxysmal AF which may lead to an underestimation of AF incidence [19]. Conversely, four studies demonstrate an increased cardiovascular morbidity and mortality in patients that were TSH suppressed [18, 21, 25, 27]. Two further studies assumed TSH suppression to adhere to national guidelines, however numerical TSH measurements were not recorded or attainable [22, 23]. Hence in these papers it is difficult to draw specific conclusions between TSH suppression and cardiovascular disease.

It is of note that although Hesselink et al. did not find a relationship between TSH levels and AF, they did demonstrate that an increased cumulative dose of RAI was associated with an increased incidence of AF [19]. Similarly, two other studies found patients treated with RAI to be at higher risk of cardiovascular morbidity compared to those who did not receive RAI [21, 25]. All patients in the study by Zoltek et al. received both TSH suppression and RAI therapy. However, these subgroups were not stratified in their analyses, hence it is difficult to deduce an association between cardiovascular morbidity and either of the therapies [23]. Further, Hesselink et al. [18] and Wang et al. [26] adjusted for RAI in their analyses. The ionising radiation in RAI therapy has the capacity to facilitate endothelial dysfunction and thus increase the risk of atherosclerotic disease [36, 37]. It has also been proposed that the cycling from subclinical hyperthyroidism to hypothyroidism, when withdrawing thyroxine therapy to allow RAI therapy, may contribute to rhythm disturbances [19]. Thus to adequately interpret the effects of TSH suppressive therapy there is a need to adjust analyses for concomitant RAI therapy.

Limitations

There are a few limitations associated with this review. Significant heterogeneity exists across studies with respect to treatment regimes, outcome variables, demographic features, follow up, control cohorts, pre-existing comorbidities, and subsequent adjustment of analyses. Different studies conducted their own adjustment analyses and it was not standardised across the included studies.

Hence it was not unexpected that the I^2 values for the outcomes in the meta-analysis were largely in the medium to high range. It was difficult to conduct subgroup or sensitivity analyses based on differing degrees of TSH suppression due to the existing heterogeneity and variable reporting of TSH levels. This could be performed in future reviews if the included papers contained more accurate reporting of TSH levels. In addition, the outcomes of AF, IHD and stroke were skewed towards the findings of Suh et al. as their sample size was significantly larger than any other study in this review.

The definition for TSH suppression varied significantly between studies and it is known that patients are stratified to differing degrees of TSH suppression based on their risk of cancer recurrence, such that higher risk patients tend to be treated with more aggressive TSH suppressive therapy and are more likely to receive RAI

[6, 7]. Changing guidelines for TSH suppression are also unaccounted with baseline data collection ranging from 1970 to 2016 across the studies in this review. Further, when reporting degree of TSH suppression, two studies assumed suppressive therapy to be within national guidelines [22, 23]. Without reported TSH values, this assumes concordant treatment paradigms across each study's respective country as well as patient compliance. Further, Suh et al. measured levothyroxine dose as a proxy marker for TSH suppression, however serum levels of TSH may vary with metabolism, age, sex, weight, and a number of other variables [27]. Similarly, patient compliance with medication was not considered in this study.

Another limitation of the review exists in the differing definitions of cardiovascular outcomes between studies. With respect to cerebrovascular disease, two studies reported on cerebrovascular disease [21, 25], whilst two others reported specifically on stroke [22, 27]. Further, Zoltek et al. defined separate subgroups for cerebral infarction and cerebrovascular disease [23]. For the purposes of this review, both stroke and cerebrovascular disease were combined as an outcome. The study by Park et al. did not have a specific ischaemic heart disease subgroup but rather a broader 'heart disease' subgroup [25]. This was combined into the subgroup titled ischaemic/coronary heart disease in this review hence all occurrences were assumed to be IHD related.

Conclusion

This study found that DTC patients who are subject to long term TSH-suppression are at higher risk of adverse cardiovascular outcomes, specifically AF, stroke, and all-cause mortality. However, there was significant diversity in study methodology and presentation of findings. Further investigation through larger scale, prospective studies with similar methodology, stringent measurement of TSH levels and adequate adjustment for confounders and comorbidities would better characterise the effects of TSH suppression therapy in DTC patients. Notwithstanding, TSH suppressive therapy for DTC patients requires dynamic assessment and follow up with respect to cardiovascular health. Patients and clinicians must be aware of these increased risks and hence a high clinical suspicion of cardiovascular disease is warranted in TSH-suppressed DTC patients.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

- [1] Rossi ED, Pantanowitz L, Hornick JL A worldwide journey of thyroid cancer incidence centred on tumour histology. *Lancet Diabetes Endocrinol* 2021; 9: 193–194
- [2] Morris LG, Sikora AG, Tosteson TD et al. The increasing incidence of thyroid cancer: the influence of access to care. *Thyroid* 2013; 23: 885–891
- [3] Cabanillas ME, McFadden DG, Durante C Thyroid cancer. *Lancet* 2016; 388: 2783–2795
- [4] Ganly I, Nixon IJ, Wang LY et al. Survival from differentiated thyroid cancer: what has age got to do with it? *Thyroid* 2015; 25: 1106–1114
- [5] Lundgren CI, Hall P, Ekblom A et al. Incidence and survival of Swedish patients with differentiated thyroid cancer. *Int J Cancer* 2003; 106: 569–573
- [6] Brabant G Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? *J Clin Endocrinol Metab* 2008; 93: 1167–1169
- [7] Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* 2006; 154: 787–803
- [8] Santos Palacios S, Pascual-Corrales E, Galofre JC Management of subclinical hyperthyroidism. *Int J Endocrinol Metab* 2012; 10: 490–496
- [9] Biondi B, Palmieri EA, Klain M et al. Subclinical hyperthyroidism: clinical features and treatment options. *Eur J Endocrinol* 2005; 152: 1–9
- [10] Collet TH, Gussekloo J, Bauer DC et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. *Arch Intern Med* 2012; 172: 799–809
- [11] Biondi B, Kahaly GJ Cardiovascular involvement in patients with different causes of hyperthyroidism. *Nat Rev Endocrinol* 2010; 6: 431–443
- [12] Biondi B, Palmieri EA, Lombardi G et al. Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. *J Clin Endocrinol Metab* 2002; 87: 968–974
- [13] Smit JW, Eustatia-Rutten CF, Corssmit EP et al. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. *J Clin Endocrinol Metab* 2005; 90: 6041–6047
- [14] Shargorodsky M, Serov S, Gavish D et al. Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. *Thyroid* 2006; 16: 381–386
- [15] Horne MK 3rd, Singh KK, Rosenfeld KG et al. Is thyroid hormone suppression therapy prothrombotic? *J Clin Endocrinol Metab* 2004; 89: 4469–4473
- [16] American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2009; 19: 1167–1214
- [17] Do Cao C, Wemeau JL Risk-benefit ratio for TSH-suppressive levothyroxine therapy in differentiated thyroid cancer. *Ann Endocrinol (Paris)* 2015; 76: 1S47–52S47
- [18] Klein Hesselink EN, Klein Hesselink MS, de Bock GH et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. *J Clin Oncol* 2013; 31: 4046–4053
- [19] Klein Hesselink EN, Lefrandt JD, Schuurmans EP et al. Increased risk of atrial fibrillation after treatment for differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 2015; 100: 4563–4569
- [20] Klein Hesselink MS, Bocca G, Hummel YM et al. Diastolic dysfunction is common in survivors of pediatric differentiated thyroid carcinoma. *Thyroid* 2017; 27: 1481–1489
- [21] Pajamaki N, Metso S, Hakala T et al. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. *Clin Endocrinol (Oxf)* 2018; 88: 303–310
- [22] Toulis KA, Viola D, Gkoutos G et al. Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease. *Clin Endocrinol (Oxf)* 2019; 91: 323–330
- [23] Zoltek M, Andersson TM, Hedman C et al. Cardiovascular incidence in 6900 patients with differentiated thyroid cancer: a Swedish nationwide study. *World J Surg* 2020; 44: 436–441

- [24] Abonowara A, Quraishi A, Sapp JL et al. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer. *Clin Invest Med* 2012; 35: E152–E156
- [25] Park J, Blackburn BE, Ganz PA et al. Risk Factors for cardiovascular disease among thyroid cancer survivors: findings from the Utah cancer survivors study. *J Clin Endocrinol Metab* 2018; 103: 2468–2477
- [26] Wang LY, Smith AW, Palmer FL et al. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. *Thyroid* 2015; 25: 300–307
- [27] Suh B, Shin DW, Park Y et al. Increased cardiovascular risk in thyroid cancer patients taking levothyroxine: a nationwide cohort study in Korea. *Eur J Endocrinol* 2019; 180: 11–20
- [28] Bielecka-Dabrowa A, Mikhailidis DP, Rysz J et al. The mechanisms of atrial fibrillation in hyperthyroidism. *Thyroid Res* 2009; 2: 4
- [29] Squizzato A, Gerdes VE, Brandjes DP et al. Thyroid diseases and cerebrovascular disease. *Stroke* 2005; 36: 2302–2310
- [30] Sheu JJ, Kang JH, Lin HC et al. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. *Stroke* 2010; 41: 961–966
- [31] Brito JP, Hay ID, Morris JC Low risk papillary thyroid cancer. *BMJ* 2014; 348: g3045
- [32] Eustatia-Rutten CF, Corssmit EP, Biermasz NR et al. Survival and death causes in differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 2006; 91: 313–319
- [33] Flynn RW, Bonellie SR, Jung RT et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. *J Clin Endocrinol Metab* 2010; 95: 186–193
- [34] Sundaram V, Hanna AN, Koneru L et al. Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. *J Clin Endocrinol Metab* 1997; 82: 3421–3424
- [35] Wang R, Yang L, Jin S et al. Thyroid stimulating hormone suppression time on cardiac function of patients with differentiated thyroid carcinoma. *Cancer Cell Int* 2018; 18: 189
- [36] la Cour JL, Hedemann-Jensen P, Sogaard-Hansen J et al. Modeling the absorbed dose to the common carotid arteries following radioiodine treatment of benign thyroid disease. *Ann Nucl Med* 2013; 27: 862–866
- [37] la Cour JL, Jensen LT, Vej-Hansen A et al. Radioiodine therapy increases the risk of cerebrovascular events in hyperthyroid and euthyroid patients. *Eur J Endocrinol* 2025; 172: 771–778